WO2008029208A1 - Use of polyols to obtain stable polymorphous forms of rifaximin - Google Patents
Use of polyols to obtain stable polymorphous forms of rifaximin Download PDFInfo
- Publication number
- WO2008029208A1 WO2008029208A1 PCT/IB2007/002199 IB2007002199W WO2008029208A1 WO 2008029208 A1 WO2008029208 A1 WO 2008029208A1 IB 2007002199 W IB2007002199 W IB 2007002199W WO 2008029208 A1 WO2008029208 A1 WO 2008029208A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rifaximin
- polyols
- water content
- polymorphous
- residual water
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
- C07D499/48—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical
- C07D499/58—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical
- C07D499/64—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- Rifaximin is an antibiotic belonging to the rifampicin family, available in tablets, granules for oral suspension and ointment, marketed in Europe, in the U.S.A. and in many other countries.
- the different rifaximin polymorphous forms can be favourably used as homogeneous and pure products in the manufacturing of the medicinal products containing rifaximin, as the efficacy and the safety of the product can be modulated by using the right polymorphous form.
- X is hydrogen or lower alkyl and n can range from 1 to 20, or 1 ,2,3-propanetriol and 1 ,2-propanediol.
- those of formula H-[O-CH 2 -CH 2 ] n -OH and their mixture (where n can range between 2 and 16) as well as the compounds 1 ,2,3-propanetriol and 1 ,2- propanediol are very important, because they are all used in the preparation of pharmaceutical formulations for humans and animals, and moreover they have a plasticizing property that can make them useful as additives in pharmaceutical preparations involving coating, such as granules and tablets.
- the object of the present invention is the use of polyols above described to stabilize rifaximin polymorphous forms, in particular the ⁇ form as disclosed by Viscomi G. C. et al., in US 7,045,620B1 (2003), so as to obtain a pharmaceutical preparation containing the ⁇ form of rifaximin, wherein the residual water content of the active ingredient rifaximin is lower than 4.5% (w/w), and to maintain polymorph ⁇ unchanged during the production stage that can directly or indirectly lead to the drying of rifaximin, that is under conditions that, without the use of polyols, would not allow to conserve the ⁇ form, which would indeed be transformed into another polymorphous form of rifaximin, depending on the severity of the applied drying condition.
- the interaction process between one of these polyols described above, or a mixture of them, and the rifaximin can be obtained by any procedure known in the pharmaceutical technology field which permits a close mixing of the components.
- One of these polyols, or a mixture of them can be applied after a suitable water dilution with a granulation process in which the solution is opportunely added to the powder containing the active ingredient, or exclusively constituted by it, with suitable mixing.
- the operation can be carried out in a traditional granulator or in a high speed granulator where a rotary blade and a breaker are present to favour the mixing of the components.
- Comparative Example 3 This example demonstrates the importance of the presence of the hydroxy group in a polyol to obtain a rifaximin in the polymorphous ⁇ form with residual water content lower than 4.5%.
- the operations are the same as those described in example 1, where 1,2-propanediol is substituted by a polyol having the esterified hydroxy group, for example 1 ,2,3-propanetriol triacetate.
- the solid components are homogenously dispersed in demineralised water with a high speed Ultra Turrax homogenizer.
- the homogenized suspension is loaded in the Wurster type apparatus with a peristaltic pump and nebulised on the rifaximin powder mixture and Aerosil® 200 at a pressure comprised between 1.0 and 1.5 bar, through a 1.8 mm nozzle.
- thermo-welded bags 9.12 Kg of gastroresistant rifaximin microgranules prepared according to the example 5, 19.58 Kg of sorbitol, 0.49 Kg of aspartame, 0.21 Kg of anhydrous citric acid, 2.10 Kg of pectin, 2.10 Kg of mannitol, 0.21 Kg of neohesperidine DC, 1.12 Kg of cherry flavour and 0.07 Kg of silica gel are sieved on a 0,5 mm mesh sieve and then mixed for 20 minutes in a V mixer. The resulting mixture is partitioned and placed in thermo-welded bags containing 5 grams of product corresponding to 800 mg of rifaximin. The composition of the medicinal speciality contained in the thermo-welded bag is reported in the following Table 3. Table 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Priority Applications (28)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200900282A EA015002B1 (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
AU2007293266A AU2007293266B2 (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
US12/439,094 US8217054B2 (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
NZ574625A NZ574625A (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
ES07804680.2T ES2626236T3 (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphic forms of rifaximin |
MX2009002445A MX2009002445A (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin. |
JP2009526185A JP5399903B2 (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphic forms of rifaxamine |
CN2007800330052A CN101511343B (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
LTEP07804680.2T LT2059232T (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
UAA200811412A UA97108C2 (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
RS20170520A RS56024B1 (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
MEP-2009-81A ME00600B (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
KR1020097004604A KR101279477B1 (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
CA2645724A CA2645724C (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
EP07804680.2A EP2059232B1 (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
KR1020127001116A KR101359327B1 (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
DK07804680.2T DK2059232T3 (en) | 2006-09-05 | 2007-07-31 | USING POLYOLS TO GET STABLE POLYMORPHE FORMS OF RIFAXIMIN |
BRPI0715853A BRPI0715853B8 (en) | 2006-09-05 | 2007-07-31 | use of polyols containing at least two hydroxy groups to stabilize polymorphic forms of rifaximin, rifaximin beta, their medicinal preparations, their microgranules and their preparation process |
SI200731941A SI2059232T1 (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
NO20083988A NO345200B1 (en) | 2006-09-05 | 2008-09-19 | Use of polyols to obtain stable polymorphic forms of rifaximin |
TN2009000030A TN2009000030A1 (en) | 2006-09-05 | 2009-01-28 | Use of polyols to obtain stable polymorphous forms of rifaximin |
IL196800A IL196800A (en) | 2006-09-05 | 2009-01-29 | Use of polyols to prepare stable polymorphous forms of rifaximin |
HR20090198A HRP20090198A9 (en) | 2006-09-05 | 2009-04-03 | Use of polyols to obtain stable polymorphous forms of rifaximin |
US13/544,945 US8748449B2 (en) | 2006-09-05 | 2012-07-09 | Use of polyols to obtain stable polymorphous forms of rifaximin |
US14/263,845 US20150072002A1 (en) | 2006-09-05 | 2014-04-28 | Use of polyols to obtain stable polymorphous forms of rifaxmin |
US15/153,636 US10280177B2 (en) | 2006-09-05 | 2016-05-12 | Use of polyols to obtain stable polymorphous forms of rifaximin |
HRP20170770TT HRP20170770T1 (en) | 2006-09-05 | 2017-05-23 | Use of polyols to obtain stable polymorphous forms of rifaximin |
CY20171100546T CY1119132T1 (en) | 2006-09-05 | 2017-05-26 | USE OF POLYOLOLS FOR TAKING STABLE RIFAXIMIN VARIOUS FORMS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2006A001692 | 2006-09-05 | ||
IT001692A ITMI20061692A1 (en) | 2006-09-05 | 2006-09-05 | USE OF POLYOLS TO OBTAIN STYLE POLYMORPHIC FORMS OF RIFAXIMINA |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/439,094 A-371-Of-International US8217054B2 (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
US13/544,945 Division US8748449B2 (en) | 2006-09-05 | 2012-07-09 | Use of polyols to obtain stable polymorphous forms of rifaximin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008029208A1 true WO2008029208A1 (en) | 2008-03-13 |
Family
ID=38714944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2007/002199 WO2008029208A1 (en) | 2006-09-05 | 2007-07-31 | Use of polyols to obtain stable polymorphous forms of rifaximin |
Country Status (34)
Country | Link |
---|---|
US (4) | US8217054B2 (en) |
EP (2) | EP3187174A1 (en) |
JP (1) | JP5399903B2 (en) |
KR (2) | KR101279477B1 (en) |
CN (1) | CN101511343B (en) |
AR (1) | AR062383A1 (en) |
AU (1) | AU2007293266B2 (en) |
BR (1) | BRPI0715853B8 (en) |
CA (1) | CA2645724C (en) |
CY (1) | CY1119132T1 (en) |
DK (1) | DK2059232T3 (en) |
EA (1) | EA015002B1 (en) |
ES (1) | ES2626236T3 (en) |
HR (2) | HRP20090198A9 (en) |
HU (1) | HUE034300T2 (en) |
IL (1) | IL196800A (en) |
IT (1) | ITMI20061692A1 (en) |
JO (1) | JO3640B1 (en) |
LT (1) | LT2059232T (en) |
MA (1) | MA30726B1 (en) |
ME (1) | ME00600B (en) |
MX (1) | MX2009002445A (en) |
MY (1) | MY178450A (en) |
NO (1) | NO345200B1 (en) |
NZ (1) | NZ574625A (en) |
PL (1) | PL2059232T3 (en) |
PT (1) | PT2059232T (en) |
RS (1) | RS56024B1 (en) |
SI (1) | SI2059232T1 (en) |
TN (1) | TN2009000030A1 (en) |
TW (1) | TWI335822B (en) |
UA (1) | UA97108C2 (en) |
WO (1) | WO2008029208A1 (en) |
ZA (1) | ZA200900833B (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7709634B2 (en) | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
WO2012038898A1 (en) | 2010-09-22 | 2012-03-29 | Alfa Wassermann S.P.A. | Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease |
US8518949B2 (en) | 2005-03-03 | 2013-08-27 | Alfa Wassermann S.P.A. | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
WO2014091432A1 (en) * | 2012-12-12 | 2014-06-19 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of rifaximin |
US9133217B2 (en) | 2011-02-11 | 2015-09-15 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
US9452157B2 (en) | 2012-07-06 | 2016-09-27 | Alfa Wassermann S.P.A | Pharmaceutical compositions comprising rifaximin and amino acids, preparation methods and use thereof |
US9498442B2 (en) | 2010-03-05 | 2016-11-22 | Alfa Wassermann S.P.A. | Rifaximin powder, process for preparing the same an controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect |
EP2059232B1 (en) | 2006-09-05 | 2017-04-19 | ALFA WASSERMANN S.p.A. | Use of polyols to obtain stable polymorphous forms of rifaximin |
US9938298B2 (en) | 2014-05-12 | 2018-04-10 | Alfa Wassermann S.P.A. | Solvated crystal form of rifaximin, production, compositions and uses thereof |
WO2018197538A1 (en) * | 2017-04-26 | 2018-11-01 | Sandoz Ag | Oral dosage form comprising rifaximin in form beta |
US10258610B2 (en) | 2011-07-29 | 2019-04-16 | Alfasigma S.P.A. | Pharmaceutical compositions comprising rifaximin, processes for their preparation and their use in the treatment of vaginal infections |
US10285944B2 (en) | 2005-03-07 | 2019-05-14 | Alfasigma S.P.A. | Gastroresistant pharmaceutical formulations containing rifaximin |
US10556915B2 (en) | 2014-03-31 | 2020-02-11 | Euticals Spa | Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011110930A2 (en) * | 2010-03-10 | 2011-09-15 | Lupin Limited | Rifaximin ready-to-use suspension |
CA2876737A1 (en) | 2012-06-13 | 2013-12-19 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
JP2016516988A (en) | 2013-03-15 | 2016-06-09 | アルファ ワッセルマン ソシエタ ペル アチオニAlfa Wassermann S.P.A. | Methods for diagnosing vaginal infection |
MX2015011802A (en) | 2013-03-15 | 2016-01-08 | Alfa Wassermann Spa | Rifaximin for use in the treating of vaginal infections. |
MX2015014307A (en) * | 2013-04-12 | 2015-12-08 | Alfa Wassermann Spa | Nsaid administration and related compositions, methods and systems. |
US9474699B2 (en) * | 2014-03-31 | 2016-10-25 | Johnson & Johnson Consumer Inc. | Compostions and methods for enhancing the topical application of a basic benefit agent |
KR101997341B1 (en) * | 2017-09-05 | 2019-10-01 | 고려대학교 세종산학협력단 | Thin film transistor and method of fabricating of the same |
FR3123563A1 (en) * | 2021-06-03 | 2022-12-09 | Algotherapeutix | Use of amitriptyline and/or one of its pharmaceutically acceptable salts as a preservative |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1676847A1 (en) * | 2003-11-07 | 2006-07-05 | ALFA WASSERMANN S.p.A. | Polymorphous forms of rifaximin as antibiotics |
WO2006094737A2 (en) * | 2005-03-07 | 2006-09-14 | Alfa Wassermann S.P.A. | Gastroresistant pharmaceutical formulations containing rifaximin |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1154655B (en) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | IMIDAZO-RIFAMYCIN DERIVATIVES METHODS FOR THEIR PREPARATION AND USE AS AN ANTIBACTERIAL ACTION SUBSTANCE |
US4462928A (en) * | 1983-03-31 | 1984-07-31 | Texaco Inc. | Partial oxidation of heavy refinery fractions |
GB8333815D0 (en) | 1983-12-20 | 1984-02-01 | Procter & Gamble | Fabric softeners |
IT1199374B (en) | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | PROCESS FOR THE PREPARATION OF PIRIDO-IMIDAZO-RIFAMICINE |
GB2253346A (en) | 1991-02-22 | 1992-09-09 | John Rhodes | Delayed release oral dosage forms for treatment of intestinal disorders |
IT1245907B (en) | 1991-05-17 | 1994-10-25 | Alfa Wassermann Spa | USE OF GLYCOSAMINOGLICANS IN THE TREATMENT OF DIABETIC NEPHROPATHY AND DIABETIC NEUROPATHY. |
DE69212497T2 (en) | 1991-12-05 | 1996-12-12 | Mallinckrodt Veterinary Inc | GLASS-LIKE CARBOHYDRATE MATRICE FOR THE ADMINISTRATION OF MEDICINES WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES |
IT1253711B (en) | 1991-12-17 | 1995-08-23 | Alfa Wassermann Spa | VAGINAL PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS |
IT1264494B1 (en) | 1993-03-23 | 1996-09-24 | Alfa Wassermann Spa | USE OF RIFAXIMIN AND FORMULATIONS THAT CONTAIN IT IN THE TREATMENT OF GASTRIC DYSPEPSIES ORIGINATED BY HELICOBACTER |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
US20010055613A1 (en) | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
US20030157174A1 (en) | 2000-03-23 | 2003-08-21 | Takayuki Tsukuda | Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component |
US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
US20040260188A1 (en) | 2003-06-17 | 2004-12-23 | The General Hospital Corporation | Automated auscultation system |
MX2007000632A (en) | 2004-07-16 | 2007-03-30 | Cipla Ltd | Anti-histaminic composition. |
DE102005004518A1 (en) | 2005-01-31 | 2006-10-12 | Behr Gmbh & Co. Kg | Expansion tank for a coolant for a cooling circuit, in particular for a low temperature circuit for indirect charge air cooling for an internal combustion engine, cooling circuit, in particular low temperature circuit for indirect charge air cooling for an internal combustion engine, method for cooling a hot component, in particular an internal combustion engine |
SI1698630T1 (en) | 2005-03-03 | 2015-01-30 | Alfa Wassermann S.P.A. | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
ITMI20061692A1 (en) * | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | USE OF POLYOLS TO OBTAIN STYLE POLYMORPHIC FORMS OF RIFAXIMINA |
WO2009047801A1 (en) | 2007-10-10 | 2009-04-16 | Lupin Limited | Therapeutic combinations and compositions for the treatment of gastrointestinal disorders |
KR102456997B1 (en) | 2009-10-27 | 2022-10-19 | 루핀 리미티드 | Solid dispersion of rifaximin |
IT1401253B1 (en) | 2010-04-23 | 2013-07-18 | Uni Degli Studi Carlo Bo Urbino | USE OF SULODEXIDE FOR THE REDUCTION OF MATRIX METALLOPROTEINASE. |
IT1403847B1 (en) | 2010-09-22 | 2013-11-08 | Alfa Wassermann Spa | PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA AND THEIR USE. |
WO2012155981A1 (en) | 2011-05-19 | 2012-11-22 | Friulchem Spa | New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby |
US9018225B1 (en) | 2013-07-26 | 2015-04-28 | Novel Laboratories | Rifaximin crystalline forms and methods of preparation thereof |
-
2006
- 2006-09-05 IT IT001692A patent/ITMI20061692A1/en unknown
-
2007
- 2007-07-30 TW TW096127714A patent/TWI335822B/en active
- 2007-07-31 ZA ZA200900833A patent/ZA200900833B/en unknown
- 2007-07-31 RS RS20170520A patent/RS56024B1/en unknown
- 2007-07-31 KR KR1020097004604A patent/KR101279477B1/en active IP Right Grant
- 2007-07-31 KR KR1020127001116A patent/KR101359327B1/en active IP Right Grant
- 2007-07-31 ME MEP-2009-81A patent/ME00600B/en unknown
- 2007-07-31 US US12/439,094 patent/US8217054B2/en active Active
- 2007-07-31 UA UAA200811412A patent/UA97108C2/en unknown
- 2007-07-31 MY MYPI20090549A patent/MY178450A/en unknown
- 2007-07-31 BR BRPI0715853A patent/BRPI0715853B8/en active IP Right Grant
- 2007-07-31 EP EP17157159.9A patent/EP3187174A1/en not_active Withdrawn
- 2007-07-31 MX MX2009002445A patent/MX2009002445A/en active IP Right Grant
- 2007-07-31 HU HUE07804680A patent/HUE034300T2/en unknown
- 2007-07-31 DK DK07804680.2T patent/DK2059232T3/en active
- 2007-07-31 CN CN2007800330052A patent/CN101511343B/en active Active
- 2007-07-31 AU AU2007293266A patent/AU2007293266B2/en active Active
- 2007-07-31 NZ NZ574625A patent/NZ574625A/en unknown
- 2007-07-31 EA EA200900282A patent/EA015002B1/en unknown
- 2007-07-31 ES ES07804680.2T patent/ES2626236T3/en active Active
- 2007-07-31 JP JP2009526185A patent/JP5399903B2/en active Active
- 2007-07-31 PL PL07804680T patent/PL2059232T3/en unknown
- 2007-07-31 EP EP07804680.2A patent/EP2059232B1/en active Active
- 2007-07-31 WO PCT/IB2007/002199 patent/WO2008029208A1/en active Application Filing
- 2007-07-31 PT PT78046802T patent/PT2059232T/en unknown
- 2007-07-31 SI SI200731941A patent/SI2059232T1/en unknown
- 2007-07-31 LT LTEP07804680.2T patent/LT2059232T/en unknown
- 2007-07-31 CA CA2645724A patent/CA2645724C/en active Active
- 2007-08-15 AR ARP070103627A patent/AR062383A1/en not_active Application Discontinuation
- 2007-09-05 JO JOP/2007/0373A patent/JO3640B1/en active
-
2008
- 2008-09-19 NO NO20083988A patent/NO345200B1/en unknown
-
2009
- 2009-01-28 TN TN2009000030A patent/TN2009000030A1/en unknown
- 2009-01-29 IL IL196800A patent/IL196800A/en active IP Right Grant
- 2009-03-30 MA MA31743A patent/MA30726B1/en unknown
- 2009-04-03 HR HR20090198A patent/HRP20090198A9/en not_active Application Discontinuation
-
2012
- 2012-07-09 US US13/544,945 patent/US8748449B2/en active Active
-
2014
- 2014-04-28 US US14/263,845 patent/US20150072002A1/en not_active Abandoned
-
2016
- 2016-05-12 US US15/153,636 patent/US10280177B2/en active Active
-
2017
- 2017-05-23 HR HRP20170770TT patent/HRP20170770T1/en unknown
- 2017-05-26 CY CY20171100546T patent/CY1119132T1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1676847A1 (en) * | 2003-11-07 | 2006-07-05 | ALFA WASSERMANN S.p.A. | Polymorphous forms of rifaximin as antibiotics |
WO2006094737A2 (en) * | 2005-03-07 | 2006-09-14 | Alfa Wassermann S.P.A. | Gastroresistant pharmaceutical formulations containing rifaximin |
Non-Patent Citations (3)
Title |
---|
KIBBE ARTHUR H.: "Handbook of Pharmaceutical Excipients", 2000, AMERICAN PHARMACEUTICAL ASSOCIATION AND PHARMACEUTICAL PRESS, USA, XP002461298 * |
LI Q ET AL: "Solvothermal growth of vaterite in the presence of ethylene glycol, 1,2-propanediol and glycerin", JOURNAL OF CRYSTAL GROWTH, NORTH-HOLLAND PUBLISHING, AMSTERDAM, NL, vol. 236, no. 1-3, March 2002 (2002-03-01), pages 357 - 362, XP004339690, ISSN: 0022-0248 * |
URESTI R M ET AL: "Effect of sugars and polyols on the functional and mechanical properties of pressure-treated arrowtooth flounder (Atheresthes stomias) proteins", FOOD HYDROCOLLOIDS, ELSEVIER, vol. 19, no. 6, November 2005 (2005-11-01), pages 964 - 973, XP004932158, ISSN: 0268-005X * |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10703763B2 (en) | 2005-03-03 | 2020-07-07 | Alfasigma S.P.A. | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
US8518949B2 (en) | 2005-03-03 | 2013-08-27 | Alfa Wassermann S.P.A. | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
US10285944B2 (en) | 2005-03-07 | 2019-05-14 | Alfasigma S.P.A. | Gastroresistant pharmaceutical formulations containing rifaximin |
EP2059232B1 (en) | 2006-09-05 | 2017-04-19 | ALFA WASSERMANN S.p.A. | Use of polyols to obtain stable polymorphous forms of rifaximin |
US10280177B2 (en) | 2006-09-05 | 2019-05-07 | Alfasigma S.P.A. | Use of polyols to obtain stable polymorphous forms of rifaximin |
US7709634B2 (en) | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
US9498442B2 (en) | 2010-03-05 | 2016-11-22 | Alfa Wassermann S.P.A. | Rifaximin powder, process for preparing the same an controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect |
AU2011306444B2 (en) * | 2010-09-22 | 2015-04-23 | Alfasigma S.P.A. | Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease |
US20170071916A1 (en) * | 2010-09-22 | 2017-03-16 | Alfa Wassermann S.P.A. | Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease |
EA027588B1 (en) * | 2010-09-22 | 2017-08-31 | Альфа Вассерманн С.П.А. | Tablet for treating crohn's disease and use thereof for this purpose |
EP2618819B1 (en) | 2010-09-22 | 2017-11-01 | Alfasigma S.p.A. | Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease |
WO2012038898A1 (en) | 2010-09-22 | 2012-03-29 | Alfa Wassermann S.P.A. | Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease |
US9133217B2 (en) | 2011-02-11 | 2015-09-15 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
US10258610B2 (en) | 2011-07-29 | 2019-04-16 | Alfasigma S.P.A. | Pharmaceutical compositions comprising rifaximin, processes for their preparation and their use in the treatment of vaginal infections |
US9452157B2 (en) | 2012-07-06 | 2016-09-27 | Alfa Wassermann S.P.A | Pharmaceutical compositions comprising rifaximin and amino acids, preparation methods and use thereof |
US9849090B2 (en) | 2012-12-12 | 2017-12-26 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of rifaximin |
WO2014091432A1 (en) * | 2012-12-12 | 2014-06-19 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of rifaximin |
US10556915B2 (en) | 2014-03-31 | 2020-02-11 | Euticals Spa | Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations |
US10745415B2 (en) | 2014-03-31 | 2020-08-18 | Amri Italy S.R.L. | Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations |
US10961257B2 (en) | 2014-03-31 | 2021-03-30 | Amri Italy S.R.L. | Polymorphic mixture of rifaximin and its use for the preparation of solid formulations |
US11739099B2 (en) | 2014-03-31 | 2023-08-29 | Curia Ip Holdings, Llc | Polymorphic mixture of Rifaximin and its use for the preparation of solid formulations |
US9938298B2 (en) | 2014-05-12 | 2018-04-10 | Alfa Wassermann S.P.A. | Solvated crystal form of rifaximin, production, compositions and uses thereof |
US10428086B2 (en) | 2014-05-12 | 2019-10-01 | Alfasigma S.P.A. | Solvated crystal form of rifaximin, production, compositions and uses thereof |
WO2018197538A1 (en) * | 2017-04-26 | 2018-11-01 | Sandoz Ag | Oral dosage form comprising rifaximin in form beta |
AU2018211305B2 (en) * | 2017-04-26 | 2019-07-25 | Sandoz Ag | Oral dosage form comprising rifaximin in form beta |
US11052071B2 (en) | 2017-04-26 | 2021-07-06 | Sandoz Ag | Oral dosage form comprising rifaximin in form beta |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10280177B2 (en) | Use of polyols to obtain stable polymorphous forms of rifaximin | |
KR101157220B1 (en) | Gastroresistant pharmaceutical formulations containing rifaximin | |
US20040028737A1 (en) | Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same | |
KR20120101439A (en) | Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof | |
KR20090092288A (en) | Pharmaceutical formulation comprising neurokinin antagonist | |
WO2012172461A1 (en) | Pharmaceutical compositions of febuxostat | |
CN111405900B (en) | Solid dispersion | |
WO1999055313A1 (en) | Pellets having a core coated with a lipid lowering agent and a polymer | |
KR100981751B1 (en) | Granules containing pranlukast and processes for the preparation thereof | |
HUT70759A (en) | Stabile pharmaceutical compositions containing ipsapiron having retard effect | |
WO2024095137A1 (en) | Pharmaceutical composition of empagliflozin and process thereof | |
WO2016122421A1 (en) | Stable pharmaceutical compositions containing prasugrel base | |
WO2006100574A1 (en) | Amorphous cefditoren pivoxil granules and processes for the preparation thereof | |
WO2005004919A2 (en) | Extended release systems for macrolide antibiotics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780033005.2 Country of ref document: CN |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07804680 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2645724 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2009000055 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12009500210 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 574625 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09010383 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007293266 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12439094 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009030276 Country of ref document: EG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009526185 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097004604 Country of ref document: KR Ref document number: 200900282 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2007293266 Country of ref document: AU Date of ref document: 20070731 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2007804680 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/002445 Country of ref document: MX Ref document number: 2007804680 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 546/MUMNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20090198A Country of ref document: HR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020127001116 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0715853 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090220 |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2017/0520 Country of ref document: RS |